Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Injected bimatoprost 0.03% solution did not effectively treat female-pattern hair loss.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

The new hyaluronic acid gel is as safe and effective for lip enhancement as the existing product.

More research is needed to understand if GLP-1 agonists affect hair health.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.

IL-23 inhibitors may help treat other skin conditions, but more research is needed.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Raltegravir may cause hair loss in some patients.

A new mutation in the human glucocorticoid receptor reduces its function and causes resistance to glucocorticoids.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.